Drug intelligence / Profile preview

Tri-Shield First Defense

Development stage
Unknown
Lead developer
ImmuCell
Modality
Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

Tri-Shield First Defense is a USDA-licensed, colostrum-derived veterinary biologic given as a single oral gel dose to newborn beef and dairy calves to provide passive immunity against K99+ Escherichia coli, bovine coronavirus, and bovine rotavirus, three major causes of neonatal calf diarrhea (scours). It consists of highly concentrated bovine immunoglobulins from hyperimmunized colostrum that bind and neutralize these enteric pathogens in the gastrointestinal tract and, when administered before gut closure, are partially absorbed systemically and later re-secreted into the gut, extending protection. The product is positioned as an antibody therapy rather than a vaccine, eliminating the need for dam- or calf-level scours vaccination, and has been shown in controlled studies to reduce mortality, morbidity, severity and duration of scours, and rotavirus shedding in newborn calves.

Brand names
Tri-Shield First DefenseFirst Defense Tri-ShieldTri-Shield
Other names
First Defense Tri-Shield
02

Targets

RVA (Rotavirus A)F5 (Coagulation Factor V)

Beyond the preview

Go deeper on Tri-Shield First Defense.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tri-Shield First Defense.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call